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Abstract
Background: The high mortality impact of infectious diseases will increase due to accelerated evolution of antibiotic
resistance in important human pathogens. Development of antibiotic resistance is a evolutionary process inducing the
erosion of the effectiveness of our arsenal of antibiotics. Resistance is not necessarily limited to a single class of antibacterial
agents but may affect many unrelated compounds; this is termed ‘multidrug resistance’ (MDR). The major mechanism of
MDR is the active expulsion of drugs by bacterial pumps; the treatment of Gram negative bacterial infections is
compromised due to resistance mechanisms including the expression of efflux pumps that actively expel various usual
antibiotics (ß-lactams, quinolones, …).
Methodology/Principal Findings: Enterobacter aerogenes has emerged among Enterobacteriaceae associated hospital
infections during the last twenty years due to its faculty of adaptation to antibiotic stresses. Clinical isolates of E. aerogenes
belonging to two strain collections isolated in 1995 and 2003 respectively, were screened to assess the involvement of efflux
pumps in antibiotic resistance. Drug susceptibility assays were performed on all bacterial isolates and an efflux pump
inhibitor (PAßN) previously characterized allowed to decipher the role of efflux in the resistance. Accumulation of labelled
chloramphenicol was monitored in the presence of an energy poison to determine the involvement of active efflux on the
antibiotic intracellular concentrations. The presence of the PAßN-susceptible efflux system was also identified in resistant E.
aerogenes strains.
Conclusions/Significance: For the first time a noticeable increase in clinical isolates containing an efflux mechanism
susceptible to pump inhibitor is report within an 8 year period. After the emergence of extended spectrum ß-lactamases in
E. aerogenes and the recent characterisation of porin mutations in clinical isolates, this study describing an increase in
inhibitor-susceptible efflux throws light on a new step in the evolution of mechanism in E. aerogenes.
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Introduction
Among Enterobacteriaceae associated hospital infections, Enterobac-
ter aerogenes has emerged during the last twenty years due to its
efficient adaptative response to environmental stresses [1]. This
common hospital pathogen in Europe is involved in nosocomial
respiratory tract and urinary infectious diseases [2–8]. This
behaviour has been associated with a decreased susceptibility to
the most recently developed cephalosporins, including cefepime
and cefpirome (last cephalosporin generation), and to carbape-
nems [4,9–11]. An increasing number of clinical E. aerogenes strains
exhibits a plasmid encoding extended-spectrum ß-lactamase
associated with an aminoglycoside enzymatic resistance in
addition to a chromosomal cephalosporinase and the clinical
isolates present also an acquired resistance, via target mutation, to
other antibiotic classes such as quinolones [2,4–15]. The
regulation of envelope permeability including the synthesis of
porins, the modification of lipopolysaccharide and the expression
of efflux pumps has been reported by several studies:(i) a strong
correlation has been reported between the absence of the E.
aerogenes major porin, Omp36, and imipenem resistance, (ii) some
isolates showing a resistance towards polymyxin group had a
simultaneous alteration of the lipopolysaccharide structure and,
(iii) in multi-drug resistant (MDR) strains the expression of an
efflux pump has been demonstrated to contribute to a severe
decrease in intracellular concentrations of various antibiotic classes
[3,4,10,12,13,16]. It has been demonstrated that during 5 days of
imipenem treatment, clinical isolates had developed imipenem
resistance via a decrease of porin synthesis conjointly to a
production of efflux system [4,17]. This tremendous capacity to
rapidly develop antibiotic resistance has been associated to the
regulation cascade involving the mar regulon and ramA regulator
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Bacterial efflux pumps represent an active protection mechanism
against toxic compounds and the major efflux pump, AcrAB-
TolC, identified in E. aerogenes clinical isolates expels a variety of
compounds including detergents and structurally unrelated
antimicrobial agents such as quinolones, tetracyclines and
chloramphenicol [18–21]. The activity of efflux pump in various
resistant clinical isolates has been characterized by using different
efflux pump inhibitors that compete with the antibiotic efflux or
with an energy poison that collapses the membrane potential
required for the active antibiotic transport [22–24].
The poly-specificity of efflux transporters confers a general
resistance phenotype that can drive the acquisition of additional
mechanisms of antibiotic resistance such as target mutation or
secretion of enzymes that degrade antibiotics and also reinforce the
effect of these acquired mechanisms [20]. It has been recently
demonstrated that the expression of the AcrAB-TolC pump is an
important prerequisite for the selection of fluoroquinolone resistant
mutants that exhibit mutated targets (DNA gyrase) in various Gram-
negative bacteria such as Salmonella or Campylobacter, two major food-
borne pathogens involved in severe human diseases [25,26].
Consequently, the spread of this resistance mechanism and the
modulation of the different bacterial responses to antibiotic therapy
calls for the identification of efflux pump activity and their
prevalence in clinical strains. An important question addresses the
evolution of drug resistance and the dissemination of this efflux
mechanism in Gram-negative bacterial pathogens.
To this aim, we decided to analyse two E. aerogenes populations
isolated fromMarseille hospitals in1995and 2003. The local criteria
used in 1995 [10], were re-used in 2003 in order to prevent (i)
introduction of some bias caused by different procedures used by
other institutions and (ii) ecological variance due to a plethora of
variable associated with different geographic areas. These isolates
wereselectedaccording to theirnoticeablecross-resistancepatternto
cephalosporins as previously reported [10]. In addition, the
epidemiology of the E. aerogenes strains are checked in the two
collections. We thus compare the two collections for resistance to
structurally unrelated antibiotics to assess the frequency of strains
exhibiting a MDR phenotype that may reflect the production of an
efflux mechanism and to evaluate the number of strains expressing a
documented efflux pump during this 1995–2003 interval.
Results
Strain characterization and antibiotic susceptibility of E.
aerogenes isolates
The DNA restriction pattern of isolates collected during the years
1995 and 2003 were performed and analysed by pulsed field gel
electrophoresis (PFGE) to determine their relatedness. These DNA
restriction patterns werecompared according to criteriaproposed by
Tenover et al. [27]. Figure 1 illustrates a representative set of this
molecular epidemiological typing. Isolates whose patterns were
indistinguishable or differing by no more than 3 fragments were
considered to belong to the same epidemic clone. An isolate was
considered to be possibly related to the outbreak strain if their
patterns did not differ in more than 4–6 bands. The patterns were
unrelated if they showed more than 7 band differences. Forty-eight
strains were studied and 46 generated reproducible fingerprint
patterns. Among them the pattern of 21 strains was identical, 14
showed 1 to 5 band differences and 11 had a pattern with more than
6 band differences. Among these eleven strains, 3 isolates were
closely related. 35 isolates were considered to belong to the same
epidemiological prevalent clone previously reported [4,5,9,28] and
11 strains were consistent to be of different origin.
The antibiotic susceptibilities of strains collected during the
periods 1995 and 2003 were presented in Table 1–2. A large
Figure 1. PFGE of XbaI-digested genomic DNA preparations from various clinical Enterobacter aerogenes isolates. 1995 isolates: 6582,
106701, 313, 139, 120, 31, 70, 17, 49, 130, 109, 183, 52. 2003 isolates: 101979, 121653, 109688, 181243, 138074, 121435, 109709, 121652, 128500,
116621. ATCC13048 and EA27, used as reference strains. Molecular weight markers are indicated: a, 48.5 kb; b, 97 kb; c, 145.5 kb; d, 194 kb; e,
242.5 kb; f, 291 kb; g, 340 kb; h, 388 kb; i, 437 kb; j, 485 kb; h, 534 kb.
doi:10.1371/journal.pone.0003203.g001
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e.g. 61% and 74 to 83% of strains were resistant to chloramphen-
icol and tested quinolones, respectively (Table 3). Conversely, only
2% and 9% of strains were resistant to imipenem and cefepime
respectively. About 12% of tested strains harboured a susceptible
phenotype against the used antibiotics (imipenem, cefepime,
tetracycline, chloramphenicol, nalidixic acid, norfloxacin, ofloxacin,
sparfloxacin). Although chloramphenicol is now rarely used in
human therapy, a major proportion of the screened isolates
exhibited chloramphenicol resistance. In addition, these strains also
presented a high level resistance against other assayed antibiotics.
PAßN-susceptible efflux pump in E. aerogenes
We have previously demonstrated that the efflux pump inhibitor
phenylalanine-arginine ß-naphthylamide (PAßN) is able to block
the efflux involved in chloramphenicol resistance in E. aerogenes
clinical strains [13,24]. In order to evaluate the activity of this
efflux mechanism in the two collections of E. aerogenes isolates, the
effect of PAßN was assayed on the level of chloramphenicol
susceptibility. For a number of isolates, addition of PAßN caused
an increase in chloramphenicol susceptibility by at least three
dilution factors (e.g. reduction of the MIC from 8 to 1 mg/ml)
indicating the involvement of a PAßN-susceptible efflux in the
resistance. In presence of PAßN, the MIC for chloramphenicol
was noticeably decreased in about 40% of all non-susceptible
(intermediate+resistant strains, I+R) isolates tested (Table 4). This
result reflects the prevalence of a functional efflux mechanism that
is susceptible to the inhibitor in the collected strains.
It is important to note that among the total of I+Rs t r a i n s
exhibiting a PAßN-susceptible efflux mechanism, the majority were
isolated in 2003: the EPI-reversed strains were observed in a
significantly greater number of chloramphenicol resistant strains
(Table 4) selected in2003 (20/29) than those selected in 1995 (9/29).
These results indicate a noticeable increase in number of PAßN-
susceptible efflux pumps acting in the strains isolated in 2003.
Evidence of active efflux for chloramphenicol in
multiresistant E. aerogenes
The activity of efflux pump in resistant isolates harbouring a
PAßN-susceptible efflux was evaluated by measuring the intracel-
lular accumulation of radiolabelled chloramphenicol in the
reference strain and selected clinical isolates. Carbonyl cyanide
m-chlorophenylhydrazone (CCCP), was a well-described tool
allowing to characterize an energy-dependent efflux in resistant
Gram-negative bacteria [16,23,24]. The variation of intracellular
drug accumulation was evaluated in the absence and in the
presence of this membrane energy uncoupler.
Different strains representative of the two series were assayed in
addition to the susceptible ATCC strain. By comparison to the
ATCC strain, a 65% reduction in the chloramphenicol accumu-
lation was detected in all tested chloramphenicol resistant E.
aerogenes strains (Figure 2). This accumulation was significantly
increased in the presence of CCCP during the incubation: 3.5 to 5
fold increase of intracellular chloramphenicol was obtained in the
presence of the uncoupler (Figure 2). These results indicate that an
active efflux pump is involved in chloramphenicol resistance in
these isolates causing a decrease of intracellular drug concentra-
tion (Table 5).
Detection of an immunorelated-AcrA component of the
efflux pump
To analyse the correlation between multidrug resistance and the
presence of an efflux system we investigated the production of an
Table 1. Susceptibilities of the E. aerogenes isolates (1995) to
different antibiotics (MIC mg/mL)
a.
Strain IMI CEF TET CHL NAL NFL OFL SPA
0 1 4 1 256 .512 128 128 64
1 4 1 4 256 .512 256 64 4
52 4 1 8 .512 64 32 8
7 0,05 8 16 8 2 0,5 ,4 0,06
11 1 8 4 256 .512 128 128 128
12 1 4 1 8 64 0,125 ,40 , 5
16 4 128 2 128 32 16 ,4 ,0,5
17 2 4 16 .256 .512 128 32 32
19 .4 16 8 256 .512 512 128 256
20 4 1 2 128 .512 256 128 64
31 1 16 2 256 .512 128 64 128
34 .4 128 8 256 .512 512 128 128
36 2 4 .256 16 .512 512 256 128
44 4 4 16 .256 .512 256 128 256
49 .48 8 .256 .512 512 128 256
52 .41 2 6 4 .512 256 64 16
53 .41 8 .256 .512 256 128 256
54 2 64 2 16 .512 64 64 16
56 .41 6 ,0,5 256 .512 256 128 128
59 2 1 4 ,4 ,4 ,4 ,4 ,0,5
70 .48 4 .256 512 256 128 256
71 2 4 2 ,4 .512 ,4 ,48
76 2 8 1 16 .512 64 64 16
98 1 32 .512 8 128 1 ,40 , 5
104 2 32 128 256 .512 64 64 32
108 2 1 2 ,4 .512 64 32 8
109 4 4 16 .256 .512 512 128 512
115 0,5 1 2 2 .512 128 16 64
120 1 1 1 256 .512 128 16 64
124 4 1 2 2 4 0,25 ,40 , 1 2 5
130 4 1 8 .256 .512 128 128 256
135 1 1 1 2 4 0,25 ,4 ,0,03
1 3 8 4 2 444,4 ,4 ,0,5
139 2 32 1 256 .512 64 128 64
148 1 1 2 ,46 4 8 ,4 ,0,5
1 5 1 1 4 4484 ,4 0,06
179 0,5 4 2 256 .512 128 64 128
183 4 128 4 .256 .512 256 64 256
313 2 1 2 128 .512 128 64 128
317 .41 6 4 3 2 .512 32 32 16
441 4 4 8 .256 .512 256 128 256
701 .46 4 8 .256 .512 512 128 256
6582 4 4 4 256 .512 256 128 256
7237 4 32 4 256 .512 256 128 256
106701 2 1 8 .256 .512 256 128 512
aThe values are the means of three independent assays.
Antimicrobial agent abbreviations: IMI, Imipenem; CEF, Cefepime; TET,
Tetracycline; CHL, Chloramphenicol; NAL, Nalidixic acid; NFL, Norfloxacin; OFL,
Ofloxacin; SPA, Sparfloxacin.
doi:10.1371/journal.pone.0003203.t001
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energy dependent efflux of chloramphenicol [29,30]. Regarding
the expression of membrane transporters, we have recently
demonstrated that a positive signal obtained from RT-PCR is
not conclusive to conclude for the correct and functional production
ofa bacterial membraneprotein [31]. It isimportanttomention that
for membrane proteins (such as efflux transporters), several post-
translational steps down-regulate their production in addition to the
transcriptional regulation of their genes [31,32]. There are the
reasons for which the production of an active efflux immunorelated
to the AcrAB-TolC system was checked by western blot analysis
using an anti-AcrA polyclonal antibody as previously described [33].
We observed the presence of an immunorelated-AcrA protein in a
large number of resistant E. aerogenes clinical isolates compared to E.
aerogenes EAEP294 which contains an acrA gene knockout insertion.
Interestingly, the isolate 54 presented no immunorelated-AcrA
signal. Concerning EAEP294, it has been previously reported that
this strain contains another efflux pump involved in antibiotic
resistance and the anti-AcrA antibody is able to recognize an
immunorelated-AcrA protein [33,34]. Moreover, several clinical
strains exhibited a high level of AcrA-like protein production similar
to that observed in strain EAEP289, which has previously be shown
to have an increased AcrA expression [21] and a high efflux pump
activity (data not shown).
Discussion
Emergence and evolution of drug resistance mechanisms in
bacteria is an unavoidable phenomenon because it represents a
natural adaptative response to environmental stress. Among the
resistance mechanisms, high expression of drug efflux pumps is an
Table 2. Susceptibilities of the E. aerogenes isolates (2003) to
different antibiotics (MIC mg/mL)
a.
Strain IMI CEF TET CHL NAL NFL OFL SPA
100128 1 2 1 8 .512 64 128 64
101234 2 1 4 .256 .512 128 64 64
101451 1 1 2 4 8 0,25 ,4 0,06
101979 4 2 4 16 .512 128 128 256
103280 4 1 8 8 16 ,4 ,4 ,0,5
105784 4 4 4 32 .512 256 128 256
105891 2 1 0,5 8 4 0,25 ,4 0,06
106206 4 64 4 256 .512 128 128 256
107868 2 8 0,5 128 .512 128 128 128
108055 4 1 16 16 512 8 ,4 ,0,5
108418 1 2 8 .256 .512 256 128 256
108969 4 1 4 16 16 ,4 ,4 ,0,5
109688 1 4 2 16 .512 128 64 64
109709 4 2 4 16 .512 512 128 256
110199 2 1 0,5 4 8 0,25 ,4 0,06
110360 2 1 32 .256 .512 256 128 256
110721 4 1 4 16 .512 512 256 512
111631 2 1 16 .256 .512 256 128 256
112144 4 1 4 16 16 ,4 ,4 ,0,5
112446 4 1 32 32 128 ,4 ,4 ,0,5
112978 4 4 2 ,4 .512 256 64 128
113022 2 4 2 256 .512 256 128 64
115264 4 4 8 .256 .512 256 128 256
118259 1 2 4 256 .512 256 128 256
121435 2 8 8 .256 .512 512 128 256
121652 1 1 2 0,5 8 0,25 ,44
121653 1 1 2 256 .512 256 256 128
121681 2 4 4 256 .512 512 128 256
122554 0,5 4 2 128 .512 64 64 64
122791 2 4 2 64 .512 256 256 128
123258 4 1 8 16 16 ,4 ,4 ,0,5
123369 4 1 8 256 .512 256 128 256
123800 2 1 4 4 8 ,4 ,4 ,0,5
128500 1 2 4 256 .512 128 128 128
128553 .48 8 .256 .512 128 128 256
129689 4 4 8 .256 .512 256 64 256
131102 4 2 8 .256 .512 256 128 256
131150 0,5 2 4 256 .512 128 128 128
131538 .43 2 8 .256 .512 256 128 256
134146 2 1 4 32 .512 128 64 32
134147 2 1 16 64 .512 256 128 64
136160 1 2 2 16 .512 256 128 256
137454 4 1 2 4 .512 32 32 16
137464 .46 4 8 .256 .512 512 128 256
138074 1 1 1 16 .512 128 128 64
138215 1 8 1 64 .512 128 128 128
181131 2 8 4 256 .512 256 64 32
181243 4 1 4 ,41 6 ,4 ,4 ,0,5
aThe values are the means of three independent assays.
Antimicrobial agent abbreviations: IMI, Imipenem; CEF, Cefepime; TET,
Tetracycline; CHL, Chloramphenicol; NAL, Nalidixic acid; NFL, Norfloxacin; OFL,
Ofloxacin; SPA, Sparfloxacin.
doi:10.1371/journal.pone.0003203.t002
Table 3. Percentages of Enterobacter aerogenes resistant
strains.
Year
Number of
strains Number of resistant strains
IMI CEF TET CHL NAL NFL OFL SPA
MIC (mg/ml) .8 .32 .8 .16 .16 .1 .1 .2
1 9 9 5 4 5 26 8 2 93 93 73 43 6
2 0 0 3 4 8 02 5 2 83 83 73 53 7
Total 93 2 8 13 57 77 74 69 72
% 2.1 8.6 13.9 61.3 82.7 79.5 74.1 78.4
Antimicrobial agent abbreviations: IMI, Imipenem; CEF, Cefepime; TET,
Tetracycline; CHL, Chloramphenicol; NAL, Nalidixic Acid; NFL, Norfloxacin; OFL,
Ofloxacin; SPA, Sparfloxacin.
doi:10.1371/journal.pone.0003203.t003
Table 4. Effect of EPI on chloramphenicol susceptibility of E.
aerogenes strains.
Year
Number of
strains I+R
a
EP
b susceptible
I+R
EP insusceptible
I+R
1995+2003 93 70 29 41
1995 45 32 9 23
2003 48 38 20 18
I, R
a: Intermediate, Resistant.
EP
b: Efflux Pump susceptible when PAßN induces a decrease of at least 3
dilutions.
doi:10.1371/journal.pone.0003203.t004
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clinical Gram-negative bacteria isolates of many pathogens such as
Pseudomonas aeruginosa [35,36], Klebsiella pneumoniae [29,37] or E.
aerogenes [13,21].
The prevalence of an identified active efflux system in highly
resistant clinical E. aerogenes strains collected, during 1995 and 2003,
inasameareahasbeeninvestigated.Inapreliminaryscreen,thetwo
collections exhibited a similar resistance profile for tetracycline,
chloramphenicol, and the quinolones tested. In addition, molecular
epidemiological typing indicates a relatively close relationship
between the analyzed isolates and the previously major prevalent
clone identified in different hospital infections due to E. aerogenes
[4,9,11]. These results provide evidence for a stability in the
resistance phenotype between 1995–2003 in the isolation site.
As previously reported, a broad spectrum efflux pump inhibitor,
such as PAßN, may be used to discriminate between the resistance
mechanisms involved in resistant isolates and to characterize the
role of inhibitor-susceptible efflux pumps [22,24,38]. It has been
demonstrated that PAßN may increase the activity of antibiotics
which are expelled by efflux pumps such as AcrAB-TolC or
MexAB-OprM [13,22,29,38,39]. This compound has been shown
to restore the antibiotic intracellular concentration in several
Gram-negative bacteria species including E. aerogenes [24,30]. In all
cases, the level of restoration of antibiotic susceptibility depends on
the presence of additional resistance mechanisms such as target
mutations or enzymatic barriers [30,37,39–41].
An active and PAßN-susceptible drug efflux system was
evidenced in multiresistant E. aerogenes isolates. The activity of
chloramphenicol efflux was determined in the presence and
absence of PAßN, and the MICs were significantly decreased in
the presence of PAßN in 40% of chloramphenicol resistant strains.
In susceptible strains (MIC,8 mg/mL), the MICs were not
noticeably affected by PAßN. These results indicate the presence
of an efflux resistance mechanism that is reversed by PAßN
addition in some chloramphenicol resistant strains. In these
strains, the intracellular chloramphenicol concentration was
influenced by CCCP, as the addition of this uncoupler of the
proton motive force induced a substantial increase (3–5 fold) in the
level of accumulated chloramphenicol. Moreover, in some isolates,
a production of an immunorelated-AcrA efflux component was
detected suggesting the involvement of a AcrAB-like efflux pump.
It is interesting to note that from the twenty nine strains that
exhibit this PAßN-reversed efflux, twenty were isolated in 2003
and only nine were isolated in 1995. This variation indicated that
the number of strains able to expel chloramphenicol had
noticeably increased during this eight year interval. This is a
major point taking into account that chloramphenicol is rarely
used in clinical settings and the relative conservation of a resistant
phenotype in the two tested collections. This result suggests that
during this eight year period, the clinical environment, such as use
of antimicrobial products and the consequent pressure on bacterial
flora or colonizing bacteria, has selected strains expressing poly-
selective efflux pumps since the FloR pump exhibits a specific
activity for structurally-related phenicol drugs [42]. Several
chemicals, e.g. biocides, bile salts or other efflux substrates are
efficient agents for selecting bacteria that overexpress efflux pump
mechanism [43–46]. This type of resistance survey is more
restricted that global studies carried out in ESAC group [47,48] or
in the EARSS group [49] but yields interesting acute data
concerning the evolution of one bacterial species and one
resistance mechanism in a given hospital area. This selection
allows us to a better approach of the antibiotic resistance evolution
during the selected period. Regarding the resistance survey, it is
important to mention that the COST Action BM0701(see http://
Figure 2. Uptake of
14C chloramphenicol by E. aerogenes
strains. Accumulation of [
14C] chloramphenicol was measured in ATCC
type strain (A) and in clinical strains isolated during the years 1995 (B)
and 2003 (C). ATCC13048 in the absence (+) and in the presence (*)o f
CCCP; strain 106701 in the absence (%) and in the presence (&)o f
CCCP; strain 6582 in the absence (#) and in the presence (N) of CCCP;
strain 109688 in the absence (e) and in the presence (X) of CCCP;
strain 134147 in the absence (n) and in the presence of (m) CCCP. Each
point is the mean of three independent experiments. Values were
plotted as cpm/OD600 over time (s).
doi:10.1371/journal.pone.0003203.g002
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of drug efflux mechanisms from clinical to chemical aspects.
After the emergence of extended spectrum ß-lactamases in E.
aerogenes isolates and the recent characterisation of porin mutations
in clinical isolates [2,6,11,15,50], this study describing an increase
in inhibitor-susceptible efflux throws light on a new step in the
evolution of mechanism in E. aerogenes. With the recent description
of the key role of efflux pumps in favouring the acquisition of other
resistance mechanisms in Gram-negative bacteria such as target
mutation [25,26], and in bacterial pathogenesis and fitness
[51,52], the increase of the number of clinical strains overpro-
ducing efflux pumps represents a serious emerging risk for the
treatment of these infections.
Methods
Bacterial strains and growth media
A total of 93 strains of Enterobacter aerogenes were isolated in 1995
and 2003 in the hospitals of Marseille (France) from a variety of
clinical specimens (respiratory tract, secretions, blood, urinary
tract, etc …). They were selected according to their noticeable
resistance against several ß-lactam antibiotics [10]. The Enterobacter
aerogenes ATCC 15038 type strain was used as the reference
(susceptible) strain for uptake of chloramphenicol. For immuno-
detection and characterization of efflux pumps, the strains EA
ATCC 15038, EAEP289 (derivative of the clinical strain EA27)
exhibiting norfloxacin efflux and the mutant EAEP294, which
does not express AcrA were used [16,21]. Bacteria were routinely
grown in Luria Bertani (LB) or Mueller-Hinton (MH) broth at
37uC. The strain EA EP294 was grown in the presence of 50 mg/
ml kanamycin.
Antibiotic susceptibility tests
Susceptibility to imipenem, cefepime, nalidixic acid, norfloxa-
cin, ofloxacin, ciprofloxacin, sparfloxacin, chloramphenicol and
tetracycline was determined by the broth dilution method, as
previously described [16] and according to the Clinical and
Laboratory Standards Institute (http://www.clsi.org) and Comite
de l’Antibiogramme de la SFM (http://www.sfm.asso.fr/nouv/
general.php?pa=2). For the determination of MICs, approxi-
mately 10
6 cells were inoculated into 1 ml MH broth containing
twofold serial dilutions of each antibiotic. Results were read after
18 h at 37uC. The efflux pump inhibitor (EPI) phenylalanine-
arginine ß-naphthylamide, PAßN [22], was used as previously
described [24]. In this study, a fixed concentration of 26.3 mg/ml
of EPI was selected for testing clinical isolates.
The MIC was the lowest concentration of the antimicrobial agent
at which no growth was detected and resistance was defined as
previously described [10,13]. For chloramphenicol MIC#8c o r r e -
sponds to susceptible phenotype, 8,MIC,16 to an intermediate
phenotype, and 16,MIC corresponds to resistant phenotype
according to French Committee (http://www.sfm.asso.fr/nouv/
general.php?pa=2). It is important to mention that, today no
chloramphenicol breakpoint is proposed for E. aerogenes and
Enterobacter spp by specific committee (European Antimicrobial
Resistance Surveillance System, http://www.rivm.nl/earss/; Euro-
pean Committee on Antimicrobial Susceptibility Testing, http://
www.srga.org/eucastwt/WT_EUCAST.htm). An efflux pump ac-
tivity was identified when the PAßN addition induced a three fold
decrease in MIC value for an antibiotic molecule [24,29].
Epidemiological typing
E. aerogenes typing was carried out by pulsed field gel
electrophoresis (PFGE) with a CHEF-Mapper system (Bio-Rad
France) as previously described [53]. Briefly, the E. aerogenes
chromosomal DNA was digested with the restriction enzyme Xba
I. Electrophoresis was performed for 22 hours with a pulsed time
ranging from 1 to 50 s. Forty four clinical isolates from these two
collections along with two clinical strains previously isolated, EA27
and EA3 [15], and the two EA ATCC strains 13048 and 15038
were studied for PFGE profile comparison.
Measurement of chloramphenicol accumulation
Measurement of
14C chloramphenicol accumulation by intact
cells has been described previously [13,24]. Exponential-phase
bacteria grown in LB broth were pelleted, washed once, and
resuspended to a density of 10
10 CFU/ml in 50 mM sodium
phosphate buffer, pH7, containing 5 mM magnesium chloride. To
de-energize the bacteria and block the efflux process, 50 mM
carbonyl cyanide m-chlorophenylhydrazone (CCCP) was added
Table 5. Antimicrobial susceptibilities and chloramphenicol accumulation in E. aerogenes strains.
Strains (year) MIC (mg/mL)
Ratio of CHL
accumulation
a
OFL NFL CIP SPA NAL CHL TET CEF IMI
EA6582 (1995) 128 (32) 256 (256) 128 (64) 256 (32) .512 (512) 256 (64) 4 4 4 3.9
EA106701 (1995) 128 (32) 256 (256) 64 (64) 512 (32) .512 (256) .256 (64) 8 2 2 5.0
EA109688 (2003) 64 (32) 128 (128) 64 (32) 64 (4) .512 (256) 16 (1) 2 4 1 3.5
EA134147 (2003) 128 (16) 256 (256) 64 (32) 64 (4) .512 (512) 64 (,4) 16 1 2 4.0
ATCC 15038
b N.D
c 0.12 (0.12) N.D 0.06 N.D 2 (1) 0.5 0.25 0.25 1.1
EAEP294
b N.D 64 16 N.D 1024 (128) 32 (32) ,0.25 N.D N.D N.D
EAEP289
b N.D 256 32 N.D 1024 (256) 1024 (128) 8 N.D N.D N.D
EA27
b .128 256 (128) 32 .64 .128 512 (64) 16 (2) N.D N.D 3.0
aRatio of chloramphenicol accumulated at 600 s with and without CCCP.
bE. aerogenes control strains used: ATCC 15038 reference strain that expresses a normal level of the AcrAB efflux system; EAEP294 (acrA
2 deleted mutant)and EAEP289
that exhibits overexpression of the AcrAB efflux system.
cN.D: not determined.
Antimicrobial agent abbreviations: IMI, Imipenem; CEF, Cefepime; TET, Tetracycline; CHL, Chloramphenicol; NAL, Nalidixic Acid; NFL, Norfloxacin; OFL, Ofloxacin; SPA,
Sparfloxacin; CIP, Ciprofloxacin. Values in parentheses were determined in the presence of efflux pump inhibitor PAßN at 26.3 mg/ml.
doi:10.1371/journal.pone.0003203.t005
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removed at set intervals were filtered and washed. The filters were
dried and radioactivity was measured in a Packard scintillation
counter.
SDS-PAGE and immunodetection of AcrA
Exponential-phase bacteria in LB broth were pelleted and
solubilized in boiling buffer at 96uC as described elsewhere
[10,13,16]. Samples (amount corresponding to 0.02 optical density
units at 600 nm) were loaded onto SDS-polyacrylamide gels (10%
polyacrylamide, 0.1% SDS), then electrotransferred to nitrocellu-
lose membranes [16]. Membranes were probed with antibodies
raised against AcrA [33] (1:50,000 dilution). Immunoreactive
proteins were visualized with alkaline phosphatase -conjugated
anti-rabbit secondary antibodies [13,16].
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